Open AccessThe coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer
Author(s) -
Xuelu Li,
Chen Song,
Gena Huang,
Shutao Sun,
Qiao Jian,
Jun Zhao,
Zuowei Zhao,
Man Li
Publication year - 2017
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s132806
Subject(s) - breast cancer , medicine , immunohistochemistry , oncology , hazard ratio , cancer , survival analysis , proportional hazards model , overall survival , phenotype , cancer research , pathology , biology , gene , confidence interval , biochemistry
HER2 overexpression is associated with aggressive phenotypes in breast cancer, including increased tumor proliferation, greater invasiveness, and reduced overall survival. The overall response rate to HER2-targeted therapies remains <30%. There is an urgent need for the identification of efficient markers to predict patients with a poor prognosis. This study was designed to investigate the correlation between EphB4 and EphrinB2 expression and the clinicopathological characteristics of HER2-positive breast cancer.